Hey — Tim Sykes here.

So, unless you’ve been living under a rock, you probably saw the news…

Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯

We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.

This isn’t hype—this is real money chasing real AI infrastructure.

And get this… Nvidia earnings are coming up fast.
I’ve seen this setup before. And I’m telling you—it’s giving me flashbacks to the early days of the AI boom.

That’s why I dropped everything to shoot this new VSL for you.

Because I think Nvidia CEO Jensen Huang is getting ready to ignite what I’m calling the AI 2.0 catalyst.

It could be huge.

And no—this isn’t about blindly buying Nvidia.

This is about using my new AI forecasting tool—XGPT—to spot the exact tickers that could pop during this next wave.

We’re talking high-confidence, one-day profit windows. The kind that don’t wait around.

🎯 Click here to watch the video and get the free ticker XGPT just flagged.

I’ll walk you through the story, what I believe is coming next, and how to use AI to trade AI.

Look, I’ve helped mentor over 40 millionaire traders. I’ve made $7.9M trading.

And even I wish I had this tool sooner.

But now it’s your turn.

See you inside,

Tim

---

Sunday’s Bonus Article

Is Abbott’s January Pullback a Good Time to Buy? 

Authored by Thomas Hughes. Published: 1/24/2026. 

At a Glance

• Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
• Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
• A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.

Abbott Laboratories’ (NYSE: ABT) January 2026 pullback has made its stock look attractively valued. The move — driven more by market angst than by any company-specific weakness — appears to be a knee-jerk overreaction that has pushed the stock back into a buy zone.

The gold income breakthrough most investors are missing (Ad)

Gold is soaring, but while the media hypes price predictions, there’s one gold income opportunity no one’s talking about. It’s not a mining stock, not an option trade, and not physical gold you have to store. A quiet fund trading for just $15 has been delivering up to $1,152 a month to regular investors. It’s a smarter, faster way to ride gold’s surge and get paid monthly while you do it.Discover the gold income breakthrough most investors are missing.

That zone corresponds to price action from 2022–2024, when Abbott was recovering from a post-COVID revenue contraction and institutions were actively accumulating the stock.

Abbott Laboratories Growth Accelerates

Although a few metrics missed expectations in Abbott Laboratories’ Q4 results and guidance, revenue of $11.46 billion rose 4.5% year-over-year, margins improved, and adjusted earnings accelerated.

Revenue growth lagged consensus by several hundred basis points, but stronger margins helped offset that: adjusted earnings per share (EPS) increased 12%, slightly above estimates.

By segment, the results highlighted the strength of Abbott’s diversified healthcare portfolio.

Nutrition and Diagnostics contracted—Nutrition fell nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech more than offset those declines.

Established Pharmaceuticals grew about 9%, driven by generics and emerging markets; Med Tech rose roughly 12.3%, with strength across its subsegments.

Margins improved, though they slightly missed some analyst forecasts.

Product-mix shifts, Med Tech strength, reduced COVID-19 sales, and operational improvements collectively boosted margins. Management expects these trends to continue, forecasting earnings growth around 10% in 2026—outpacing revenue—and supporting its capital-return plans.

Abbott’s capital returns are central to the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and it appears positioned to continue that trend. After the pullback the stock yields about 2.5%, and the company pays out less than half of consensus earnings, leaving ample cash flow for share buybacks, which help offset dilution from share-based compensation.

Analysts Point to Robust Rebound in Abbott Laboratories Stock

Some analysts noted the revenue miss, but no major rating or price-target changes were announced the morning of the release. The prevailing view remains that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth.

MarketBeat’s consensus price target implies as much as roughly 30% upside, potentially pushing the stock to new all-time highs; even the low-end target suggests modest upside.

Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and acquisitions.

For example, the proposed acquisition of Exact Sciences would broaden Abbott’s revenue and profit streams and expand its product pipeline.

The recent decline has been sharp and could deepen, but institutions accumulated shares throughout 2025 and are likely buyers at these discounted levels.

Early technical support appears around $105–$110, though it is not yet confirmed. Shares could dip to the low end of the target buy zone—possibly to about $95 or lower—before rebounding.

This email is a paid advertisement sent on behalf of Timothy Sykes, a third-party advertiser of MarketBeat. Why was I sent this email?. 


Results are not typical and will vary from person to person. Making money trading stocks takes time, timing, proper execution, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.


If you need help with your subscription, feel free to contact our U.S. based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. USA..

From Our Partners: Two AI Stocks Getting Quiet Attention (Click to Opt-In)